Services
Online Inquiry

For research use only. Not intended for any clinical use.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Non-Human Primate (NHP) PK/PD Modeling & Simulation Service

At Creative Biolabs, our NHP PK/PD Modeling & Simulation Service offers a professional promise: Accelerate Your Drug Discovery Process! Are you currently facing long drug development cycles, high costs from extensive animal studies, or challenges in translating preclinical data to humans? Our NHP PK/PD Modeling & Simulation Service helps you streamline your preclinical pipeline, predict drug behavior with greater accuracy, and optimize dosing strategies through advanced mathematical modeling and simulation platforms.

Overview of NHP PK/PD Modeling & Simulation Service

What Our Service Is

The Creative Biolabs NHP PK/PD Modeling & Simulation Service leverages mathematical models to elucidate and forecast the intricate link between a drug's concentration in the body and its therapeutic impact. Particularly advantageous in the preclinical phase for biologics like monoclonal antibodies, this service capitalizes on the physiological and immunological parallels between NHPs and humans. Serving as a crucial conduit for translating preclinical findings into human clinical trial frameworks, it underscores the biological merits of NHPs as models. While their genetic and immune systems mirror human biology, ethical concerns and high costs necessitate minimizing their use.

Our services are applied in several critical scenarios:

  • Translating Preclinical Data to Humans: We use NHP PK/PD data to build models that predict safe and effective starting doses for first-in-human (FIH) clinical trials, minimizing risk and ensuring a smooth transition.
  • Optimizing Dosing Regimens: Our models help you identify the most effective dose, frequency, and route of administration to achieve the desired therapeutic outcome while minimizing potential toxicity.
  • Understanding Drug Behavior: We provide deep insights into a drug's ADME profile, as well as its mechanism and duration of action.

Why Choose Us?

Creative Biolabs creates significant value for our clients by addressing key pain points in preclinical development. The complexity and high cost of drug development, especially for biologics, can lead to delays and increased spending. We transform these challenges into benefits:

  • From High Cost to Cost Efficiency: By using advanced modeling and simulation, we can reduce the number of costly and time-consuming animal studies required, leading to substantial cost savings.
  • From Translational Risk to Data-Driven Decisions: We use sophisticated platforms to build robust models that provide a clear rationale for dose selection and study design, thereby de-risking the transition from preclinical to clinical phases.
  • From Long Timelines to Accelerated Development: Our streamlined workflow and rapid turnaround times enable faster decision-making, helping you accelerate your drug development pipeline.

Pipeline of construction of a NHP PK Model. (OA Literature)Fig.1 Pipeline for developing a NHP pharmacokinetic model.1

Key Benefits of Our Service

Our NHP PK/PD Modeling & Simulation Service is built on a foundation of scientific rigor, efficiency, and a deep understanding of biopharmaceutical development.

  • Rapid Response and Expertise: Our team of experienced pharmacometricians provides a swift response to your project inquiries and a high level of expertise. We have successfully completed thousands of projects, and our published data showcases a consistently high pass rate in our modeling and simulation efforts.
  • Extensive NHP Resources: Creative Biolabs collaborates with leading nonclinical research laboratories that have access to extensive NHP resources, which includes but not limited to Cynomolgus, Rhesus, Marmoset, and African Green Monkey, ensuring that your studies are conducted with the highest standards of animal welfare and scientific integrity.
  • Customization for Your Project: We understand that every drug candidate is unique. Our services are highly customizable to meet your specific project needs, whether you are developing a novel therapeutic, a biosimilar, or a gene-targeting biologic. We work closely with you to design a modeling strategy that directly addresses your key research questions.
  • In-Depth, Actionable Reporting: Our reports go beyond raw data. We provide comprehensive, annotated, and publication-ready documentation that includes clear model interpretations, simulation outcomes, and strategic recommendations for your next development steps.

How Creative Biolabs' Service Can Assist Your Project?

Our service provides clear deliverables and problem-solving capabilities, helping you navigate the complexities of preclinical development with confidence. We offer tangible solutions that lead to informed decisions, optimized trial design, and improved success rates.

01

Required Starting Materials

02

Project Scoping and Data Review

03

Model Development and Validation

04

Simulation and Sensitivity Analysis

05

Strategic Recommendations

06

Final Report and Consultation

Key Deliverables

Our service provides a suite of comprehensive deliverables to support your regulatory submissions and internal decision-making.

  • Comprehensive Lab Report: A detailed document outlining the methodology, model development, simulation results, and scientific conclusions.
  • Raw Data and Model Annotations: All the raw data used for modeling, along with the annotated models and code files for your records.
  • Presentation and Strategic Insights: A clear presentation of the key findings, including graphical representations, and actionable strategic recommendations for future studies.

Capabilities & Partnerships

Service-Specific Data

  • Annual Sample Size: Our service processes over 50,000 samples annually, contributing to a vast and growing database for model development.
  • Turnaround Time (TAT): The typical turnaround for a standard project is 6-8 weeks, depending on complexity.
  • Pass Rate: Our models have a 95% success rate in predicting the PK/PD profile in follow-on studies.

Our Valued Partners

Frequently Asked Questions

Q: How can PK/PD modeling help me reduce the number of animals in my studies?
A: Our modeling and simulation services align with the "3Rs" principle (Reduce, Refine, Replace). By using validated models, we can simulate multiple dosing scenarios and test various hypotheses on a computer rather than in a living organism. This reduces the number of animals required, saving you both time and resources.
Q: Is the NHP data I provide sufficient for modeling?
A: Our pharmacometricians are skilled at working with a variety of data sets. We will perform a preliminary data review to assess the quality and completeness of your data. In most cases, we can work with your existing data to build a robust model. If we identify any gaps, we'll provide clear recommendations on what is needed.
Q: How does your service compare to using other animal models?
A: While other animal models are useful for certain applications, NHPs have the closest physiological and immunological similarities to humans, which is crucial for biologics. Our service leverages this unique advantage to create models that are highly predictive and relevant for human translation, a capability that is often limited with other models.
Q: What if my drug candidate has unique properties?
A: Our team thrives on solving complex challenges. We have extensive experience with a wide range of drug candidates, including those with unique mechanisms of action or complex ADME profiles. We offer customizable modeling approaches to ensure that your specific research questions are addressed effectively. For more details on a specific project, feel free to contact us.

Contact Us

In summary, Creative Biolabs' NHP PK/PD Modeling & Simulation Service provides a powerful, data-driven solution to optimize your drug development pipeline. We offer a blend of scientific expertise, technological proficiency, and a collaborative approach to help you make faster, more confident decisions. Contact our team to learn more about how our services can be tailored to your project.

Reference

  1. Stader, Felix, et al. "Physiologically Based Pharmacokinetic Modeling of Biologic Case Studies in Monkeys and Humans Reveals the Necessity of an Additional Clearance Term." Pharmaceutics 17.5 (2025). Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.3390/pharmaceutics17050560
Cart
Cart